BioClin

BioClin Therapeutics is a private clinical-stage drug development company developing first-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibodies in areas of high unmet medical need. The company's lead development candidate, B-701, is a human antibody for the treatment of patients with metastatic bladder cancer or metastatic urothelial carcinoma (mUC) who have relapsed or are refractory to platinum-based therapy.